PHARMACEUTICAL COMPOSITIONS COMPRISING DGLA AND USE OF SAME
The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.
1 - 18 . (canceled)
19 . A method of treating atopic dermatitis in a subject in need thereof, the method comprising orally administering at least about 2 g of a pharmaceutical composition comprising at least about 80% dihomo gamma linolenic acid (DGLA) by weight of total fatty acids present in the pharmaceutical composition to the subject in an amount effective to treat the atopic dermatitis.
20 . The method of claim 19 , wherein the DGLA is in a form of a triglyceride, an alkyl ester, a free fatty acid, or a salt.
21 . The method of claim 19 , wherein the pharmaceutical composition is present in at least two capsules.
22 . The method of claim 21 , wherein each of the capsules comprises up to about 1 g of DGLA.
23 . The method of claim 19 , wherein the DGLA comprises at least about 85% by weight of total fatty acids present in the pharmaceutical composition.
24 . The method of claim 19 , wherein the DGLA comprises at least about 90% by weight of total fatty acids present in the pharmaceutical composition.
25 . The method of claim 19 , wherein the DGLA comprises at least about 95% by weight of total fatty acids present in the pharmaceutical composition.
26 . The method of claim 19 , wherein the pharmaceutical composition is administered to the subject daily for a period of at least about 8 weeks.
27 . The method of claim 19 , wherein the atopic dermatitis is mild atopic dermatitis.
28 . The method of claim 19 , wherein the atopic dermatitis is moderate atopic dermatitis.
29 . The method of claim 19 , wherein the atopic dermatitis is severe atopic dermatitis.
30 . A method of treating atopic dermatitis in a subject in need thereof, the method comprising orally administering at least about 2 g of a pharmaceutical composition comprising at least about 80% DGLA by weight of total fatty acids present in the pharmaceutical composition to the subject to treat the atopic dermatitis, wherein the DGLA is in a form of a triglyceride, an alkyl ester, a free fatty acid, or a salt.
31 . The method of claim 30 , wherein the pharmaceutical composition is present in at least two capsules.
32 . The method of claim 31 , wherein each of the capsules comprises up to 1 g of DGLA.
33 . The method of claim 32 , wherein the DGLA comprises at least about 85% by weight of total fatty acids present in the pharmaceutical composition.
34 . The method of claim 32 , wherein the DGLA comprises at least about 90% by weight of total fatty acids present in the pharmaceutical composition.
35 . The method of claim 32 , wherein the DGLA comprises or at least about 95% by weight of total fatty acids present in the pharmaceutical composition.
36 . The method of claim 30 , wherein the pharmaceutical composition is administered to the subject daily for a period of at least about 8 weeks.
37 . The method of claim 30 , wherein the atopic dermatitis is mild atopic dermatitis, moderate atopic dermatitis, or severe atopic dermatitis.